Search

Your search keyword '"P. G. Richardson"' showing total 21 results
Start Over Author "P. G. Richardson" Journal clinical lymphoma and myeloma
21 results on '"P. G. Richardson"'

1. A347 Phase I Trial of Perifosine, Lenalidomide, and Dexamethasone in Relapsed or Refractory Myeloma

Author

A. McAllister, Melissa Alsina, K Giusti, Todd M. Zimmerman, Andrzej Jakubowiak, Peter Sportelli, Tara Kendall, KC Anderson, C Harvey, Teru Hideshima, P. G. Richardson, Christine Brozo, Jonathan L. Kaufman, and L. Gardner

Subjects
Oncology, Cancer Research, medicine.medical_specialty, business.industry, Hematology, General Medicine, Perifosine, chemistry.chemical_compound, chemistry, Refractory, Internal medicine, Medicine, business, Dexamethasone, Lenalidomide, medicine.drug
Published
2009

2. B257 Vorinostat in Combination with Other Anti-MM Agents

Author

X-Y Pei, Syed Rizvi, V Richon, J Garcia-Vargas, S Grant, KC Anderson, P. G. Richardson, Constantine Mitsiades, and James R. Berenson

Subjects
Cancer Research, Oncology, business.industry, medicine, Hematology, General Medicine, Pharmacology, business, Vorinostat, medicine.drug
Published
2009

3. B037 CAL-101: A Selective Inhibitor of PI3K p110D for the Treatment of Multiple Myeloma

Author

Noopur Raje, Giulia Perrone, N Giese, P. G. Richardson, Gullu Gorgun, Brian Lannutti, Sonia Vallet, D Cristina, Yutaka Okawa, Loredana Santo, Mariateresa Fulciniti, KC Anderson, NC Munshi, Hiroshi Ikeda, Elisabetta Calabrese, K Puri, Teru Hideshima, and Hiroshi Yasui

Subjects
Cancer Research, Oncology, Myeloma protein, business.industry, Cancer research, medicine, Hematology, General Medicine, medicine.disease, business, PI3K/AKT/mTOR pathway, Multiple myeloma
Published
2009

4. A220 Bortezomib and Melphalan as Part of VMP Are Associated with Similar Hematologic Toxicity to MP Alone

Author

P. G. Richardson, J. Hou, KC Anderson, H van de Velde, M.A. Dimopoulos, J F San Miguel, Michel Delforge, Martin Kropff, M.T. Petrucci, Rudolf Schlag, Ofer Shpilberg, A Liu, William Deraedt, Nuriet K. Khuageva, Andrew Cakana, Viktor Rossiev, Tadeusz Robak, and M.V. Mateos

Subjects
Oncology, Melphalan, Cancer Research, medicine.medical_specialty, Bortezomib, business.industry, Hematology, General Medicine, Hematologic toxicity, Internal medicine, medicine, business, medicine.drug
Published
2009

5. A247 Bortezomib, Dexamethasone, Cyclophosphamide, Lenalidomide (VDCR) Has High Efficacy in First-Line MM

Author

R Hari, Aparna Krishnan, Iain J. Webb, R.M. Rifkin, S. J. Noga, Jeffrey L. Wolf, M Bhandari, C. Gasparetto, Ian W. Flinn, P. G. Richardson, D Grosman, Shaji Kumar, J Shi, Entezam Sahovic, Nancy Callander, Jonathan D. Glass, and S V Rajkumar

Subjects
Cancer Research, Cyclophosphamide, business.industry, First line, Hematology, General Medicine, Oncology, medicine, Russian federation, business, Humanities, Bortezomib/dexamethasone, medicine.drug, Lenalidomide
Abstract

A246 VMP Results in Fewer Bone Events and Greater ALP Increases Versus MP in the VISTA Study in Front-Line MM M Delforge,1 M Kropff,1 I Spicka,2 M Petrucci,3 PG Richardson,4 R Schlag,5 N Khuageva,6 MA Dimopoulos,7 O Shpilberg,8 O Samoilova,9 MV Mateos,10 K Liu,11 W Deraedt,12 H van de Velde,13 J San Miguel14 1University of Munster, Germany; 2University Hospital, Prague, Czech Republic; 3University La Sapienza, Rome, Italy; 4Dana-Farber Cancer Institute, Boston, MA; 5Praxisklinik Dr. Schlag, Wurzburg, Germany; 6SP Botkin Moscow City Clinical Hospital, Russian Federation; 7University of Athens, School of Medicine, Athens, Greece; 8Rabin Medical Center, Petah-Tiqva, Israel; 9Nizhnii Novgorod Region Clinical Hospital, Russian Federation; 10Hospital Universitario Salamanca, CIC, IBMCC (USAL-CSIC), Spain; 11Johnson & Johnson Pharmaceutical Research & Development, L.L.C., Raritan; 12Johnson & Johnson Pharmaceutical Research & Development, Beerse, Belgium; 13Johnson & Johnson Pharmaceutical Research & Development, Beerse, Belgium; 14Hospital Universitario Salamanca. CIC, IBMCC (USAL-CSIC), Salamanca, Spain

Published
2009

6. A533 RAD001: Phase II Trial in Relapsed/Refractory Waldenström Macroglobulinemia, the DFCI Experience

Author

A Sam, Marybeth Nelson, Renee Leduc, KC Anderson, W Berg, Kelly O’Connor, Diane Warren, Thomas E. Witzig, Jacob D. Soumerai, Eric N. Jacobsen, SP Treon, Daniel J. DeAngelo, P. G. Richardson, Irene M. Ghobrial, Brianna Harris, Aldo M. Roccaro, and Stacey Chuma

Subjects
Oncology, Cancer Research, medicine.medical_specialty, business.industry, Internal medicine, Relapsed refractory, medicine, Waldenstrom macroglobulinemia, Hematology, General Medicine, business, medicine.disease
Published
2009

7. A217 Erythropoiesis-Stimulating Agents: No Impact on Long-Term Outcome in MM Patients in the VISTA Trial

Author

M.T. Petrucci, Tadeusz Robak, M.A. Dimopoulos, H van de Velde, William Deraedt, J F San Miguel, P. G. Richardson, Andrew Cakana, Kolosova LIu, Nuriet K. Khuageva, Rudolf Schlag, M.V. Mateos, Michel Delforge, KC Anderson, Martin Kropff, Ofer Shpilberg, J. Hou, and Viktor Rossiev

Subjects
Cancer Research, medicine.medical_specialty, Oncology, business.industry, Medicine, Erythropoiesis, Hematology, General Medicine, business, Intensive care medicine, Outcome (game theory), Term (time)
Published
2009

8. A535 Phase II Trial of Bortezomib and Rituximab in Relapsed/Refractory Waldenström Macroglobulinemia

Author

KC Anderson, Aldo M. Roccaro, NC Munshi, Renee Leduc, Jeffrey V. Matous, Brianna Harris, A Sam, Jacob D. Soumerai, Robert L. Schlossman, Kelly O’Connor, Diane Warren, Irene M. Ghobrial, P. G. Richardson, Ashraf Z. Badros, SP Treon, A Birner, Stacey Chuma, Marybeth Nelson, and W Padmanabhan

Subjects
Oncology, Cancer Research, medicine.medical_specialty, Bortezomib, business.industry, Waldenstrom macroglobulinemia, Hematology, General Medicine, medicine.disease, Internal medicine, Relapsed refractory, medicine, Rituximab, business, medicine.drug
Published
2009

9. A241 Vorinostat/Lenalidomide/Dexamethasone: A Phase I Study

Author

KC Anderson, Donna M. Weber, Constantine Mitsiades, Syed Rizvi, David S. Siegel, J. Howe, D Reiser, and P. G. Richardson

Subjects
Oncology, Cancer Research, medicine.medical_specialty, business.industry, Hematology, General Medicine, Phase i study, Internal medicine, medicine, business, Vorinostat, Dexamethasone, Lenalidomide, medicine.drug
Published
2009

10. B281 Ciliary Proteins and Hedgehog Pathway in Multiple Myeloma

Author

Y-T Tai, Aldo M. Roccaro, S Blotta, Teru Hideshima, Gullu Gorgun, KC Anderson, Constantine S. Mitsiades, B Franco, Salvatore Venuta, P. G. Richardson, Klaus Podar, and Noopur Raje

Subjects
Cancer Research, Oncology, business.industry, Cancer research, medicine, Hematology, General Medicine, medicine.disease, business, Hedgehog signaling pathway, Multiple myeloma
Published
2009

11. A352 Impact of Complete Response on Quality of Life in Newly Diagnosed Multiple Myeloma Patients

Author

P. G. Richardson, HV de Velde, Ravinder Dhawan, Antoine Regnault, Juliette Meunier, Don Robinson, Andrew Cakana, K Rosa, and J F San Miguel

Subjects
Cancer Research, Pediatrics, medicine.medical_specialty, business.industry, Hematology, General Medicine, Newly diagnosed, medicine.disease, Oncology, Quality of life, medicine, business, Multiple myeloma, Complete response
Published
2009

12. A172 Peripheral Neuropathy with VMP Resolves in the Majority of Patients and Shows a Rate Plateau

Author

Nuriet K. Khuageva, M.A. Dimopoulos, Andrew Cakana, Antonio Palumbo, Ivan Spicka, Marivi Mateos, P. G. Richardson, Ofer Shpilberg, Kevin Liu, Rik Schots, J F San Miguel, Rudolf Schlag, Martin Kropff, and H van de Velde

Subjects
Cancer Research, medicine.medical_specialty, business.industry, Hematology, General Medicine, medicine.disease, Plateau (mathematics), Surgery, Peripheral neuropathy, Oncology, medicine, Radiology, business, Multiple myeloma
Published
2009

13. A235 A Prolonged Therapy Improves Quality of Response, and CR Associated with Superior Outcomes, with VMP

Author

P. G. Richardson, Rudolf Schlag, Martin Kropff, Kevin Liu, William Deraedt, M.A. Dimopoulos, Ofer Shpilberg, A. Boral, J F San Miguel, Michel Delforge, J L Harousseau, Michele Cavo, Andrew Cakana, Mieczysław Komarnicki, Rik Schots, Ruben Niesvizky, Antonio Palumbo, H van de Velde, M.V. Mateos, and Anatoly Golenkov

Subjects
Melphalan, Cancer Research, medicine.medical_specialty, business.industry, Bortezomib, Urology, Renal function, Hematology, General Medicine, medicine.disease, Thalidomide, Peripheral neuropathy, Oncology, Prednisone, Medicine, business, Multiple myeloma, medicine.drug, Lenalidomide
Abstract

Introduction and Aims: In the international, phase III VISTA trial, bortezomib (velcade) plus melphalan/prednisone (VMP) was superior to MP across all efficacy end points, including response rate, time to progression (TTP), time to subsequent therapy (TTNT), and overall survival (OS; San Miguel et al, N Eng J Med 2008). Here we present updated survival data after prolonged follow-up, and data on use of subsequent therapy. Methods: Patients were randomized to VMP (n = 344) or MP (n = 338). Patients received nine 6-week cycles of bortezomib 1.3 mg/m2 (days 1, 4, 8, 11, 22, 25, 29, 32 in cycles 1-4 and days 1, 8, 22, 29 in cycles 5-9); melphalan 9 mg/m2 and prednisone 60 mg/m2 (days 1-4 in cycles 1-9), or MP alone. Results and Conclusion: VMP offered a significant survival benefit over MP (HR = 0.64; P = .0032); median follow-up, 25.9 months. Three-year OS was 72% versus 59%, respectively. OS was not substantially affected by baseline creatinine clearance. TTNT and treatment-free interval (TFI) were also significantly longer with VMP (TTNT 28.1 months vs. 19.2 months; HR = 0.53; P < .000001; TFI 16.6 months vs. 8.4 months; HR = 0.54; P < .00001). Clinical benefits appeared greater with VMP in patients achieving a complete response versus partial response versus no response. Fewer patients in the VMP versus MP arm (38% vs. 57%, respectively) required subsequent therapy; 16% and 43% received bortezomib, 49% and 44% received thalidomide, and 19% and 6% received lenalidomide, respectively. Bortezomib re-treatment was feasible in the VMP arm (6% CR; Table 1); a 10% CR rate was observed in patients who received bortezomib after MP. Peripheral neuropathy in the VMP arm improved in 79% of events (median, 1.9 months); 60% resolved completely (median, 5.7 months).

Published
2009

14. A224 Lenalidomide, Bortezomib, and Dexamethasone Has Notable Activity in High-Risk First-Line Myeloma

Author

David Avigan, Constantine Mitsiades, Noopur Raje, Robert L. Schlossman, Sundar Jagannath, M Lauria, Irene M. Ghobrial, Sagar Lonial, Robert Knight, NC Munshi, Laura E. Lunde, KC Anderson, David H. Vesole, Diane Warren, K Shea, S Kaster, Robin Joyce, P. G. Richardson, Carol Delaney, Teru Hideshima, Deborah Doss, Amitabha Mazumder, DL Esseltine, Andrzej Jakubowiak, and R Lukas

Subjects
Gynecology, Cancer Research, medicine.medical_specialty, Bortezomib, business.industry, First line, Hematology, General Medicine, Pharmacology, Oncology, medicine, University medical, General hospital, business, Dexamethasone, Lenalidomide, medicine.drug
Abstract

A224 Lenalidomide, Bortezomib, and Dexamethasone Has Notable Activity in High-Risk First-Line Myeloma PG Richardson,1 S Lonial,1 A Jakubowiak,2 S Jagannath,3 N Raje,4 D Avigan,5 IM Ghobrial,6 R Schlossman,6 A Mazumder,3 NC Munshi,6 D Vesole,7 R Joyce,5 D Doss,6 D Warren,6 L Lunde,6 R Lukas,6 S Kaster,4 K Shea,4 C Delaney,5 M Lauria,5 C Mitsiades,6 T Hideshima,6 R Knight,8 DL Esseltine,9 KC Anderson6 1Winship Cancer Institute, Atlanta, GA; 2University of Michigan Comprehensive Cancer Center, Ann Arbor, MI; 3St. Vincent’s Comprehensive Cancer Center, New York, NY; 4Massachusetts General Hospital, Boston, MA; 5Beth Israel Deaconess Medical Center, Boston, MA; 6Dana-Farber Cancer Institute, Boston, MA; 7Division of Hematology/Oncology, Loyola University Medical Center, Maywood, IL; 8Celgene, Inc., Summit, NJ; 9Millennium: The Takeda Oncology Company, Cambridge, MA, USA

Published
2009

15. A246 VMP Results in Fewer Bone Events and Greater ALP Increases Versus MP in the VISTA Study in Front-Line MM

Author

M.A. Dimopoulos, Olga Samoilova, Rudolf Schlag, M.V. Mateos, William Deraedt, Kolosova LIu, Ofer Shpilberg, H van de Velde, P. G. Richardson, M.T. Petrucci, J F San Miguel, Nuriet K. Khuageva, Martin Kropff, Michel Delforge, and Ivan Spicka

Subjects
Cancer Research, medicine.medical_specialty, Oncology, business.industry, Medicine, Russian federation, Front line, Hematology, General Medicine, business, Humanities, Surgery
Abstract

A246 VMP Results in Fewer Bone Events and Greater ALP Increases Versus MP in the VISTA Study in Front-Line MM M Delforge,1 M Kropff,1 I Spicka,2 M Petrucci,3 PG Richardson,4 R Schlag,5 N Khuageva,6 MA Dimopoulos,7 O Shpilberg,8 O Samoilova,9 MV Mateos,10 K Liu,11 W Deraedt,12 H van de Velde,13 J San Miguel14 1University of Munster, Germany; 2University Hospital, Prague, Czech Republic; 3University La Sapienza, Rome, Italy; 4Dana-Farber Cancer Institute, Boston, MA; 5Praxisklinik Dr. Schlag, Wurzburg, Germany; 6SP Botkin Moscow City Clinical Hospital, Russian Federation; 7University of Athens, School of Medicine, Athens, Greece; 8Rabin Medical Center, Petah-Tiqva, Israel; 9Nizhnii Novgorod Region Clinical Hospital, Russian Federation; 10Hospital Universitario Salamanca, CIC, IBMCC (USAL-CSIC), Spain; 11Johnson & Johnson Pharmaceutical Research & Development, L.L.C., Raritan; 12Johnson & Johnson Pharmaceutical Research & Development, Beerse, Belgium; 13Johnson & Johnson Pharmaceutical Research & Development, Beerse, Belgium; 14Hospital Universitario Salamanca. CIC, IBMCC (USAL-CSIC), Salamanca, Spain

Published
2009

16. A166 VMP in Renally Impaired Newly Diagnosed MM Patients: Cohort Analysis of the VISTA Study

Author

Rudolf Schlag, Andrew Cakana, Ofer Shpilberg, Tamás Masszi, P. G. Richardson, Julia Alexeeva, Martin Kropff, MA Dimopoulos, Nuriet K. Khuageva, Rik Schots, M.V. Mateos, H van de Velde, M Petruci, J F San Miguel, Michel Delforge, V Deraedt, E Kastritis, and Kevin Liu

Subjects
Cancer Research, Oncology, Nursing, business.industry, Medicine, Russian federation, Hematology, General Medicine, Newly diagnosed, business, Humanities, Cohort study
Abstract

A166 VMP in Renally Impaired Newly Diagnosed MM Patients: Cohort Analysis of the VISTA Study MA Dimopoulos,1 PG Richardson,1 R Schlag,2 NK Khuageva,3 O Shpilberg,4 E Kastritis,5 M Kropff,6 M Petruci,7 M Delforge,8 J Alexeeva,9 R Schots,8 T Masszi,10 MV Mateos,11 V Deraedt,12 K Liu,13 A Cakana,14 H van de Velde,12 J San Miguel11 1Dana-Farber Cancer Institute, Boston, MA; 2Praxisklinik Dr. Schlag, Wurzburg, Germany; 3SP Botkin Moscow City Clinical Hospital, Russian Federation; 4Rabin Medical Center, Petah-Tiqva, Israel; 5Alexandra Hospital, University of Athens, School of Medicine, Athens, Greece; 6University of Munster, Germany; 7University La Sapienza, Rome, Italy; 8Myeloma Study Group, Belgian Hematological Society, Belgium; 9St Petersburg, Russia; 10St. Istvan and St. Laszlo Hospital of Budapest, Budapest, Hungary; 11Hospital Universitario Salamanca. CIC, IBMCC (USAL-CSIC), Salamanca, Spain; 12Johnson & Johnson Pharmaceutical Research & Development, Beerse, Belgium; 13Johnson & Johnson Pharmaceutical Research & Development, L.L.C., Raritan, NJ; 14Johnson & Johnson Pharmaceutical Research & Development, High Wycombe, UK

Published
2009

17. A349 Phase I/II Trial of Perifosine + Bortezomib in Rel/Ref MM Patients Previously Treated with Bortezomib

Author

Aparna Krishnan, K O'Riley, Jeffrey L. Wolf, Robert L. Schlossman, NC Munshi, D. Irwin, Jeffrey A. Zonder, Jacob P. Laubach, L. Gardner, John J. Densmore, KC Anderson, D Tocco, Tara Kendall, Irene M. Ghobrial, Peter Sportelli, Dixil Francis, Noopur Raje, Teru Hideshima, Andrzej Jakubowiak, P. G. Richardson, Thomas Martin, S. Lonial, Kathleen Colson, E Steinfield, S Dean, and Michael Bar

Subjects
Cancer Research, business.industry, Bortezomib, Hematology, General Medicine, Perifosine, chemistry.chemical_compound, Phase i ii, Oncology, chemistry, Cancer research, Medicine, business, Previously treated, medicine.drug
Published
2009

18. A227 Lenalidomide, Bortezomib, and Dexamethasone Is Active in High-Risk Relapsed/Refractory Myeloma

Author

Melissa Alsina, Irene M. Ghobrial, Colson, Amitabha Mazumder, Lunde, NC Munshi, Esseltine, Andrzej Jakubowiak, Teru Hideshima, McKenney, KC Anderson, Kosakowski, Knight, S. Lonial, Sundar Jagannath, Kennedy, Noopur Raje, P. G. Richardson, Constantine Mitsiades, Robert L. Schlossman, and David H. Vesole

Subjects
Oncology, Cancer Research, medicine.medical_specialty, business.industry, Bortezomib, Hematology, General Medicine, Internal medicine, Relapsed refractory, medicine, University medical, General hospital, business, Dexamethasone, medicine.drug, Lenalidomide
Abstract

A224 Lenalidomide, Bortezomib, and Dexamethasone Has Notable Activity in High-Risk First-Line Myeloma PG Richardson,1 S Lonial,1 A Jakubowiak,2 S Jagannath,3 N Raje,4 D Avigan,5 IM Ghobrial,6 R Schlossman,6 A Mazumder,3 NC Munshi,6 D Vesole,7 R Joyce,5 D Doss,6 D Warren,6 L Lunde,6 R Lukas,6 S Kaster,4 K Shea,4 C Delaney,5 M Lauria,5 C Mitsiades,6 T Hideshima,6 R Knight,8 DL Esseltine,9 KC Anderson6 1Winship Cancer Institute, Atlanta, GA; 2University of Michigan Comprehensive Cancer Center, Ann Arbor, MI; 3St. Vincent’s Comprehensive Cancer Center, New York, NY; 4Massachusetts General Hospital, Boston, MA; 5Beth Israel Deaconess Medical Center, Boston, MA; 6Dana-Farber Cancer Institute, Boston, MA; 7Division of Hematology/Oncology, Loyola University Medical Center, Maywood, IL; 8Celgene, Inc., Summit, NJ; 9Millennium: The Takeda Oncology Company, Cambridge, MA, USA

Published
2009

19. A084 Similar Benefit in Patients Aged q 75 Years Versus < 75 Years with VMP in First-Line MM and Bortezomib in Relapsed MM

Author

Nuriet K. Khuageva, Rudolf Schlag, Martin Kropff, J F San Miguel, Rachel Neuwirth, P. G. Richardson, H van de Velde, M.A. Dimopoulos, Kolosova LIu, William Deraedt, Ofer Shpilberg, Rik Schots, Anthony Boral, M.T. Petrucci, and Andrew Cakana

Subjects
Cancer Research, Oncology, business.industry, First line, Medicine, Russian federation, In patient, Hematology, General Medicine, business, Humanities
Abstract

A084 Similar Benefit in Patients Aged 75 Years Versus < 75 Years with VMP in First-Line MM and Bortezomib in Relapsed MM M Kropff,1 PG Richardson,1 R Schlag,2 N Khuageva,3 MA Dimopoulos,4 O Shpilberg,5 R Schots,6 M Petrucci,7 R Neuwirth,8 A Boral,8 A Cakana,9 K Liu,10 W Deraedt,11 H Van de Velde,11 J San Miguel12 1Dana-Farber Cancer Institute, Boston, MA; 2Praxisklinik Dr. Schlag, Wurzburg, Germany; 3SP Botkin Moscow City Clinical Hospital, Russian Federation; 4University of Athens School of Medicine, Greece; 5Rabin Medical Center, Petah-Tiqva, Israel; 6Myeloma Study Group Belgian Hematological Society, Belgium; 7University La Sapienza, Rome, Italy; 8Millennium: The Takeda Oncology Company, Cambridge, MA; 9Johnson & Johnson Pharmaceutical Research & Development, High Wycombe, UK; 10Johnson & Johnson Pharmaceutical Research & Development, L.L.C., Raritan, USA; 11Johnson & Johnson Pharmaceutical Research & Development, Beerse, Belgium; 12Hospital Universitario Salamanca. CIC, IBMCC (USAL-CSIC), Salamanca, Spain

Published
2009

20. A534 Perifosine: Final Results of a Phase II Trial in Relapsed/Refractory Waldenström Macroglobulinemia

Author

Renee Leduc, F Hong, Edie Weller, Irene M. Ghobrial, A Sam, Aldo M. Roccaro, Nancy Rubin, Brianna Harris, KC Anderson, K C'Connor, Stacey Chuma, Marybeth Nelson, SP Treon, Peter Sportelli, Xavier Leleu, Diane Warren, and P. G. Richardson

Subjects
Oncology, Cancer Research, medicine.medical_specialty, business.industry, Waldenstrom macroglobulinemia, Hematology, General Medicine, medicine.disease, Perifosine, chemistry.chemical_compound, chemistry, Internal medicine, Relapsed refractory, medicine, business
Published
2009

21. A573 Phase I Trial of CCI-779 and Weekly Bortezomib in Relapsed and/or Refractory Multiple Myeloma

Author

P. G. Richardson, E Campagnaro, Aldo M. Roccaro, Jacob P. Laubach, NC Munshi, Robert L. Schlossman, A Birner, Kathleen Colson, Stacey Chuma, V Dixon-Lipscomb, Ravi Vij, Kelly O’Connor, Diane Warren, AM Dollard, A Sam, Irene M. Ghobrial, Brianna Harris, Renee Leduc, Marybeth Nelson, and KC Anderson

Subjects
Oncology, Cancer Research, medicine.medical_specialty, Bortezomib, business.industry, Internal medicine, medicine, Refractory Multiple Myeloma, Hematology, General Medicine, business, medicine.drug
Published
2009

Catalog

Books, media, physical & digital resources
See catalog results